TREATMENT OF CANCER WITH A PI3K INHIBITOR IN A PATIENT PRESELECTED FOR HAVING A PIK3CA MUTATION IN THE CTDNA

• 收藏
• 分享

专利权人:

发明人:

申请号：

EP16808813.6

公开号：

EP3383391A1

申请日:

2016.11.30

申请国别(地区):

EP

年份:

2018

代理人:

摘要：

The present invention relates in part to the selective cancer therapy scheme based on the chemical examination that whether there is PI3K mutation in blood or blood serum sample from cancer patient. The cancer with 5- (2,Bis--morpholines of 6- -4- bases-pyrimidine-4-yl) -4- trifluoromethylpyridins -2- bases amine or its hydrochloride, or (S)-pyrrolidines -1,2- dicarboxylic acids 2- amides 1- (4- methyl -5- [2- (2,2,2- tri- fluoro- 1,1- dimethyl-ethyIs)-pyridin-4-yl]-thiazol-2-yl }-amide) treatment.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/